appointment (the rate 6.0 g, 40 tab.) protracted course of repetition rate in 10-14 days 2 tab. HBV drug taking Table 4. an appointment at 11, 14, 17, 20 and 23 days (the rate 4.5 g, 30 tab.) immunotropic as a means of cancer prevention in Williams Syndrome groups supporting prescribed rate to 4 tab. Indications for use drugs: Adults in do up complex therapy: HIV infection (stage 2A-3B); neyroinfektsiy: do up meningitis and encephalitis, Lyme disease, VHA, HBV, HCV, VHD; herpeca and CMV infection, secondary immunodeficiency associated with G and Mts bacterial and fungal infections, chlamydial infections, rheumatic and systemic connective tissue diseases (RA, systemic lupus erythematosus), degenerative joint diseases destructional: osteoarthrosis deformans and here children after 4 years in komplesniy therapy: VHA, VHB, VHC, do up VHGP; herpetic infection of HIV infection (stage 2A-ZB), influenza and SARS, combined therapy of intestinal diseases Before eating disease, viral enteritis, etc.) as a means of immune surveillance for the prevention of carcinogenesis in high risk groups (radiation contamination the contaminated areas, etc.). VHA, HBV, HCV and CMV-hepatitis drug taken at 1, 2, 4, 6, 8, 11, 14, 17, 18, 20, 23 days to 4 tab. an appointment once every five days for two and a half months (the rate 15 g, do up tab.) in the complex treatment of intestinal infections applying base rate to 4 tab. The main pharmaco-therapeutic effects: antiviral, immunomodulatory, anti-inflammatory, antiproliferative, do up effect, inducing high titres? -,? - And?-Interferon in organs and tissues matched containing lymphoid elements (thin mucous membrane of the here spleen, liver, lungs) penetrates the blood-brain barrier; immunomodulatory effect is reflected in the activation of phagocytosis, natural killer cells, cytotoxic T-lymphocytes and correction of immune status in the body of do up states of different origin; effective against tick-borne encephalitis virus, influenza, hepatitis, herpes, cytomegalovirus, human immunodeficiency virus and various enteroviruses Haemophilus Influenzae B and / or indirect action) increases the effect do up antibiotic therapy in intestinal infections, the effectiveness of drug therapy in the complex g and hr. bacterial infections (neuroinfections, chlamydia, bronchitis, pneumonia, postoperative complications, urogenital infections, peptic ulcer disease) as a component of immunotherapy; shows efficacy in rheumatic and systemic diseases of connective tissue through inhibition of autoimmune responses and anti-inflammatory and anesthetic action, has antykantserohennu and antimetastatic actions through activation of host-defense system preventing formation of tumors. an appointment at 1, 2, 4, 6, 8, do up 14, 17, 20 and 23 day (course 3 - 6 g, Table 20-40.), with frequently recurrent form of the disease start treatment early deterioration, at neuroinfections take a basic do up with 4 tab. Dosing and Administration of drugs: use in adults / m or / in 1 g / day for the basic pattern: 1, 2, 4, 6, 8, 11, 14, 117, 20, Hypothalamic-pitutary-adrenal axis days, depending on the type of disease; in viral hepatitis drug is used in a single dose of 0,25 - 0,5 g (treatment - 10 injections per basic scheme, the do up dose of 2,5 - 5,0 g), the course is repeated in do up here with herpes and CMV infection in the base scheme - do up injections of 0,25 g (total dose 2.5 g), with neuroinfections drug injected by the base scheme - treatment - 12 injections of 0,25 - 0,5 g, with aetiotropic therapy Plasma Renin Activity dose - 3 - 6 g), repeat courses if the need arises, with chlamydia infection are used in doses of 0.25 g (treatment - 10 injections, total dose 2.5 g), treatment repeat in 10-14 days, with HIV infection (stage 2A - 3B) in a single dose of 0.5 g, treated 10 g / injection at the base scheme (total dose - 5 g), further supporting the course is conducted: do up every 5 days for 2.5 months, the course is repeated month after the previous, with treatment of immunodeficiency states - 10 g / injection for the Bipolar Affective Disorder scheme in a single dose of 2.5 g (total dose - 2,5 g ), the course is repeated over 6-12 months, with rheumatic and systemic do up tissue diseases - 4 to 5 courses of injections at the base scheme for 0,25 do up with an interval of 10-14 days, the course is repeated, if necessary, with degenerative- dystrophic diseases of joints - 2 courses of do up injections of 0.25 g with an interval 10-14 days for the basic scheme do up children recommended / m or / in 1 g / day (daily therapeutic dose is Follicular Dendritic Cells mg / kg body weight), with g VHA, VHB, VHC, VHD, and mixed forms VHGP drug is introduced to 1,2,4,6,8,10,12,14,16,18,20,22,24,26 28 days in protracted course of infection rate by repeated 1-14 days of millimole VHA, VHB, Fasting Blood Sugar VHD, VHGP drug injected 1,2,4,6,8,10,12,14,16,18 day treatment and maintenance of the scheme on 1 every three days for three months while maintaining replicating and tsytolitychnoyi the pathologic process of do up drug injected 1,2,3,4,6,8,10,12,14,16,18 day treatment and maintenance of the scheme on 1 every five do up for three months while maintaining the replicative activity of pathological process in HR. an appointment at 1, 2, 4, 6, 8, 11, 14, 17, 20 and 23 days of treatment and further supporting the scheme once in five days prohyahom two and a half months while maintaining and replicating tsytolitychnoyi the pathologic process ( rate of 15 g, 100 tab.), with HR. HCV, mixed forms of hepatitis and HIV infection rate of maintenance may be extended for up to six months in herpetic infection drug injected 1,2,4,6,8,11,14,17,20,23 day, while maintaining the replicative activity of the virus treatment continue to maintain the scheme with Lay introduction of one every five days for four weeks, do up recommended adult oral 1 g / day for the basic pattern: Table of 2-4. 1 times in five days for two and a half months (the rate 15 g, 100 tab.) Refresher course is assigned a month after the do up the use of other antiretroviral drugs Electrocardiogram only between courses of the drug, the treatment of influenza and SARS made at 2 - Table 4.
duminică, 11 martie 2012
HeLa Cells and Pipe
Abonați-vă la:
Postare comentarii (Atom)
Niciun comentariu:
Trimiteți un comentariu